Showing 5091-5100 of 6978 results for "".
- Neurotrimin Identified as Key Target for Keloid Treatment: Analysishttps://practicaldermatology.com/news/neurotrimin-identified-key-target-keloid-treatment-analysis/2470778/Researchers for a new genetic study have identified seven proteins as potential drug targets for the treatment of keloids, with neurotrimin (NTM) emerging as a particularly significant finding. Publishing in the Journal of Investigative Dermatology, the study design employed a two-sample M
- National Rosacea Society Introduces Informational Postcardhttps://practicaldermatology.com/news/national-rosacea-society-introduces-informational-postcard/2470763/The National Rosacea Society (NRS) announced today that it has released a new educational postcard to raise awareness about rosacea, a chronic skin condition affecting over 16 million Americans. Titled “Rosacea: A Common Disease, Uncommonly Treated,” the resource is designed for d
- ADapt Study: Lebrikizumab Improves Skin and Quality of Life in ADhttps://practicaldermatology.com/news/study-lebrikizumab-improves-skin-and-quality-life-ad/2470753/Results from the phase 3b ADapt study presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference indicated lebrikizumab (LEB) improved skin clearance, reduced itch, and enhanced quality of life in patients with moderate-to-severe atopic dermatitis (AD) in whom dupilumab (DUPI) was
- Advanced Neuroprotein Technique Linked with Improved Aesthetic Resultshttps://practicaldermatology.com/news/advanced-neuroprotein-technique-linked-improved-aesthetic-results/2468758/A study evaluating the use of botulinic neuroprotein combined with low molecular weight hyaluronic acid (LMWHA) and lyophilized amino acids in a single syringe showed enhanced outcomes in aesthetic treatments. The study included patients treated with a single injection session. According t
- FDA Clears Illuminate PRP System for Clinical Usehttps://practicaldermatology.com/news/fda-clears-illuminate-prp-system-clinical-use/2468757/Illuminate PRP’s platelet-rich plasma (PRP) system has received FDA clearance for clinical use, the company announced. The FDA-cleared single-spin PRP system offers a fast, efficient method for preparing high-quality PRP with high platelet capture rates, providing physicians with a reliabl
- Study Highlights Gaps in Fitzpatrick Skin Type Determinationhttps://practicaldermatology.com/news/study-highlights-gaps-fitzpatrick-skin-type-determination/2468709/New research published in The Journal of Clinical and Aesthetic Dermatology evaluated concordance between self-assessed and provider-determined Fitzpatrick skin types (FSTs). Study researchers conducted the analysis of 472 patients attending a dermatology practice and included dat
- OLYMPIA 1: Nemolizumab Shows Improvements in Prurigo Nodularis Symptomshttps://practicaldermatology.com/news/olympia-1-nemolizumab-shows-improvements-prurigo-nodularis-symptoms/2468705/Results from a multicenter phase 3 clinical trial indicated that nemolizumab monotherapy significantly reduces pruritus and nodular lesions in adults with moderate to severe prurigo nodularis (PN). Researchers for the OLYMPIA 1 trial evaluated the efficacy and safety of nemolizumab in 286
- Analysis: Dermoscopy Raises Diagnostic Odds for Melanoma Accuracyhttps://practicaldermatology.com/news/analysis-dermoscopy-raises-diagnostic-odds-melanoma-accuracy/2468666/Experienced dermatologists achieve significantly higher diagnostic accuracy for skin cancer than primary care physicians (PCPs), particularly when using dermoscopy, according to a new meta-analysis of 100 studies. The review, published in JAMA Dermatology, focused on diagnostic accuracy fo
- Dupilumab Shows Long-Term Survival Rates in Treating Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/dupilumab-shows-long-term-survival-rates-treating-moderate-severe-atopic-dermatitis/2468646/A recent literature review of published studies suggested that dupilumab maintained survival rates of 80–90% at 1, 2, and 3 years, significantly exceeding the 20-41% rates observed for cyclosporine and methotrexate during comparable periods. "The aim of this literature review is to describ
- SDPA: Strategic Supplement Strategies for the Derm PAhttps://practicaldermatology.com/news/sdpa-strategic-supplement-strategies-derm-pa/2468638/Sara Wilchowski, DMSc, MPAS, PA-C, presented “Strategic Supplement Strategies for the Derm PA” at SDPA’s 22nd Annual Fall Dermatology Conference in Las Vegas. The lecture explored the role of nutraceuticals and alternative medicines in supporting patients in their overall wellness jour